TESOLEAN Fat Burner

R450.00

TESOLEAN – Most Potent Fat loss agent to date!

  • RAPID FAT LOSS
  • INCREASED FAT OXIDATION
  • REDUCES APPETITE
  • IMPROVES INSULIN SENSITIVITY
  • INCREASES ENERGY EXPENDITURE AT REST
  • SUITABLE FOR MEN & WOMAN

Directions For Use:

  • Men: 1 – 2 tablets per day
  • Woman: 1 tablet per day

Supplement Facts:

  • Serving Size: 1 Tablet
  • Tablets Per Container: 50

13 in stock (can be backordered)

SKU: SKU000014 Category: Tag:

Description

TESOLEAN – Most Potent Fat loss agent to date!

  • RAPID FAT LOSS
  • INCREASED FAT OXIDATION
  • REDUCES APPETITE
  • IMPROVES INSULIN SENSITIVITY
  • INCREASES ENERGY EXPENDITURE AT REST
  • SUITABLE FOR MEN & WOMAN

Directions For Use:

  • Men: 1 – 2 tablets per day
  • Woman: 1 tablet per day

Supplement Facts:

  • Serving Size: 1 Tablet
  • Tablets Per Container: 100

Tesofensine (NS2330) is a serotonin–noradrenaline–dopamine reuptake inhibitor from the phenyltropane family of drugs, which is being developed for the treatment of obesity. Tesofensine was originally developed by a Danish biotechnology company, NeuroSearch, who transferred the rights to Saniona in 2014.
As of 2015, tesofensine has been discontinued for the treatment of Alzheimer’s and Parkinson’s disease but is in Phase II clinical trials for obesity.

History
Tesofensine was originally investigated for the treatment of Alzheimer’s disease and Parkinson’s disease, and was subsequently dropped from development for these applications after early trial results showed limited efficacy for treatment of these diseases. However, weight loss was consistently reported as an adverse event in the original studies, especially in overweight or obese patients. Therefore, it was decided to pursue development of tesofensine for the treatment of obesity.
Tesofensine primarily acts as an appetite suppressant, but possibly also acts by increasing resting energy expenditure. Phase 2 trials for the treatment of obesity have been successfully completed.

Pharmacology
Transporter selectivity
Tesofensine also indirectly potentiates cholinergic neurotransmission proven to have beneficial effects on cognition, particularly in learning and memory. Sustained treatment with tesofensine has been shown to increase BDNF levels in the brain and may possibly have an antidepressant effect.

Clinical trials
Phase 2b trial (TIPO-1) results reported in The Lancet showed levels of weight loss over a 6-month period that were significantly greater than those achieved with any currently available drugs. Patients lost an average of 12.8 kg on the 1 mg dose, 11.3 kg on the 0.5 mg dose and 6.7 kg on the 0.25 mg dose, compared with a 2.2 kg loss in the placebo group.
All participants were instructed to follow a diet with a 300 kcal deficit and to increase their physical activity gradually to 30–60 minutes of exercise per day. The placebo-subtracted mean weight losses were 4.5%, 9.2% and 10.6% in the 0.25 mg, 0.5 mg and 1 mg dose groups, respectively. This is approximately twice the weight loss produced by medications currently approved by the US Food and Drug Administration (FDA) for the treatment of obesity.

Adverse events
In general, the safety profile of tesofensine is similar to currently approved medications for the treatment of obesity. The most commonly reported side effects in the obese population were dry mouth, headache, nausea, insomnia, diarrhoea and constipation. A dose-dependent pattern was observed for dry mouth and insomnia. The overall withdrawal rate due to adverse events in clinical trials in the obese population was 13% with tesofensine and 6% with placebo. Blood pressure and heart rate increases with the therapeutically relevant doses of tesofensine (0.25 mg and 0.5 mg) were 1–3 mmHg and up to 8 bpm, respectively.
Main conclusions from the evaluation of tesofensine metabolic effects:

  •  Tesofensine reduces appetite sensations
    o In line with earlier clinical data from TIPO-1, the subjective appetite sensations measured after 14 days treatment in TIPO-2 showed that subjects in the tesofensine treated group had an increased feeling of satiety with less desire to eat than subjects in the placebo group
  •  Tesofensine significantly increases fat oxidation and reduces fat tissue
    o In the tesofensine treated group, 24-hour fat oxidation was increased by 15%, while, reassuringly, 24-hour protein oxidation was lower compared with the placebo group. Also, results from DEXA scanning show a statistically significantly greater loss of fat tissue in the tesofensine treated subjects than under placebo.
  • Tesofensine increases levels of adiponectin and improves insulin sensitivity
    o The significant loss of fat in the tesofensine-treated subjects was also reflected in a higher level of adiponectin in their blood. Adiponectin is a peptide hormone secreted exclusively by fat cells (adipocytes). Adiponectin decreases free fatty acids in the blood (plasma triglycerides) and increases glucose metabolism by improved insulin sensitivity, thereby also playing an important role in the treatment of type 2 diabetes.
  • Tesofensine increases energy expenditure at rest
    o After 14 days, a significant increase of 6% in night time energy expenditure was observed in the tesofensine treated group compared with placebo. The observed increase could not be explained by differences in body weight or spontaneous physical activity, indicating a direct effect of tesofensine on energy expenditure at rest.

WARNING: For use as a dietary supplement only by healthy adults the age of 18 and over. Do not use this product if you are nursing, pregnant, or attempting to become pregnant. Contains caffeine. Do not combine with other sources of caffeine or stimulants. Too much caffeine may cause nervousness, irritability, sleeplessness, and, occasionally, rapid heartbeat. Consult a physician before using this or any other dietary supplement. Do not take this product if you have any pre-existing medical conditions or if you are using any prescription or over-the-counter medication. Discontinue use and consult your health care professional if you experience any adverse reaction to this product. This may contain ingredients banned by certain sports organisations. User accepts all risks, liabilities, and consequences in regard to testing. Do not use if safety seal is broken or missing. Use only as directed. Do not exceed the recommended serving under any circumstances. KEEP OUT OF REACH OF CHILDREN.

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.